Posts

Showing posts with the label Cancer

7 Best Christmas Tree Stands in 2022

Image
Believe it or not, a Christmas tree won't stay upright on its own. Instead, you need a stable Christmas tree stand that can accommodate the type and size of tree you have. We researched dozens of the best Christmas tree stands to help you find the right one for your needs, whether you have a real tree, an artificial tree, a small tree, or a behemoth. The stands in our guide have a track record of durability, performance, and easy setup. We also outline the size and type of tree each stand is meant for. Check out our guide to the best Christmas tree skirts once you've chosen the right stand for your tree. The best Christmas tree stands in 2022 Best Christmas tree stand overall: Krinner Tree Genie Christmas Tree Stand, available at Amazon, $82.79 The German-engineered Krinner Tree Genie Christmas Tree Stand is easy to set up in a couple of minutes and keeps trees up to 12 f...

GSK, Pfizer, Sanofi escape U.S. federal litigation over Zantac

Image
Drugmakers GSK Plc, GSK-N Pfizer Inc, PFE-N Sanofi SA and Boehringer Ingelheim on Tuesday defeated thousands of lawsuits in U.S. federal court claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science. While the companies, which have all marketed the drug at different times, still face tens of thousands of similar lawsuits in state courts, the ruling by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocks out a significant portion of their potential liability. “We are extremely surprised by this miscarriage of justice and fully expect that the Eleventh Circuit Court of Appeal will reverse these rulings on appeal,” lawyers for the plaintiffs said in a joint statement. Zantac, first approved in 1983, became the world’s best selling medicine in 1988 and one of the first-ever drugs to top $1 billion in annual sales. Originally marketed by a forerunner of GSK, it was later sold successively to Pfizer, Boehringer ...

Merck and Moderna detail progress on potential skin cancer vaccine

Image
Moderna’s MRNA-Q stock soared Tuesday after the COVID-19 vaccine maker detailed progress in developing a preventive shot for a deadly form of skin cancer. The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed. The drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in survival before the cancer returned in patients with advanced melanoma. “We are very excited, we are moving very quickly with Merck onto phase 3 for this study,” Moderna CEO Stephane Bancel told CNBC Tuesday morning. Phase 3 is generally the largest and most expensive stage of clinical research before regulators review a potential drug for approval. Moderna developed one of the most popular vaccines used to protect patients against COVID-19, and the drugmaker brought in more than $3-billion from its Spikevax in this year’s third qua...

Merck and Moderna detail progress on potential skin cancer vaccine

Image
Moderna’s MRNA-Q stock soared Tuesday after the COVID-19 vaccine maker detailed progress in developing a preventive shot for a deadly form of skin cancer. The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed. The drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in survival before the cancer returned in patients with advanced melanoma. “We are very excited, we are moving very quickly with Merck onto phase 3 for this study,” Moderna CEO Stephane Bancel told CNBC Tuesday morning. Phase 3 is generally the largest and most expensive stage of clinical research before regulators review a potential drug for approval. Moderna developed one of the most popular vaccines used to protect patients against COVID-19, and the drugmaker brought in more than $3-billion from its Spikevax in this year’s third qua...

Popular posts from this blog

Pick a Ceiling Fan Based on a Room's Square Footage

An Existentialist Guide to Feeling Nothing

6 of the Best Drinking Games to Play During Super Bowl LVII